10.6084/m9.figshare.11888520.v1 Sinead Toomey Sinead Toomey Aoife Carr Aoife Carr Mateusz Mezynski Mateusz Mezynski Yasir Elamin Yasir Elamin Shereen Rafee Shereen Rafee Mattia Cremona Mattia Cremona Clare Morgan Clare Morgan Stephen Madden Stephen Madden Khairun Abdul-Jalil Khairun Abdul-Jalil Kathy Gately Kathy Gately Angela Farrelly Angela Farrelly Elaine Kay Elaine Kay Susan Kennedy Susan Kennedy Kenneth O’Byrne Kenneth O’Byrne Liam Grogan Liam Grogan Oscar Breathnach Oscar Breathnach Patrick Morris Patrick Morris Alexander Eustace Alexander Eustace Joanna Fay Joanna Fay Robert Cummins Robert Cummins Anthony O’Grady Anthony O’Grady Roshni Kalachand Roshni Kalachand Norma O’Donovan Norma O’Donovan Fergal Kelleher Fergal Kelleher Aine O’Reilly Aine O’Reilly Mark Doherty Mark Doherty John Crown John Crown Bryan Hennessy Bryan Hennessy Additional file 1 of Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples Springer Nature 2020 tumor samples metastatic tumour samples Colorectal B Table S 1. List Table S 2. Somatic mutations KRAS mutations PIK 3CA oncogenic mutations Breast tumour cohorts tumour types Table S 8. Frequency RPPA tumour samples Phase Protein Array Table S 6. Somatic mutation status catalog number Agena MassArray technology host species Table S 4. Antibodies Table S 7. Somatic mutation status 2020-02-23 04:40:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Identification_and_clinical_impact_of_potentially_actionable_somatic_oncogenic_mutations_in_solid_tumor_samples/11888520 Additional file 1: Figure S1. Breakdown of tumour types in A. Colorectal B. Lung and C. Breast tumour cohorts. Table S1. List of mutations analysed using the Agena MassArray technology. Table S2. Somatic mutations tested subdivided by pathway. Table S4. Antibodies used for Reverse Phase Protein Array (RPPA), including the company from which it was purchased, the catalog number, the host species and the dilution at which it was used. Table S6. Somatic mutation status in samples taken from two different regions of the same primary tumour. Samples identified in one sample but not in the other are identified in bold print. Table S7. Somatic mutation status of primary and matched metastatic tumour samples. Samples identified in one sample but not in the other are identified in bold print. Table S8. Frequency and co-occurrence of somatic PIK3CA and KRAS mutations in solid tumour samples.